Search

Your search keyword '"Moreno, Victor"' showing total 60 results

Search Constraints

Start Over You searched for: Author "Moreno, Victor" Remove constraint Author: "Moreno, Victor" Publication Type Conference Materials Remove constraint Publication Type: Conference Materials
60 results on '"Moreno, Victor"'

Search Results

2. 617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors

4. WHEN IS A ROBOT A COBOT? MOVING BEYOND MANUFACTURING AND ARM-BASED COBOT MANIPULATORS.

6. 6/#455 Management of immune-related adverse events in patients with solid tumors treated with dostarlimab in the garnet study

7. 770 Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors

8. 589 Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti–PD-1/PD-L1 treatment: results of a dose-optimization, exploratory phase 1b/2 trial

9. 2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer

11. Abstract 2737: Clinical and epidemiologic predictors of clonal immune responses in colorectal cancer

12. Abstract 835: T-cell abundance, clonality and disease specific survival in colorectal cancer

13. Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study

14. Abstract 881: Benchmarking genome-wide polygenic risk score development techniques in colorectal cancer risk prediction

15. Abstract LB090: Associations of somatically mutated genes and pathways with colorectal cancer specific survival in 4,500 colorectal cancer patients

16. Abstract 818: Association of polygenic risk score and menopausal hormone therapy for colorectal cancer risk

17. Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

18. Abstract 817: Probing the diabetes - colorectal cancer link using gene - environment interaction analyses

20. Abstract 824: Germline genetic regulation of the adaptive immune response in colorectal cancer

21. Abstract 815: Genome-wide gene-calcium interaction in relation to colorectal cancer risk

22. Abstract LB179: Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

23. Laser lightning rod and artificial fog dissipation

24. “Production of Biodiesel from Non Edible Vegetable Oils. A Review”

26. SD-access

27. 370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors

28. 278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+advanced non-small cell lung cancer

30. Abstract 2332: Tumor infiltrating lymphocytes, immunoSeq, and CMS classification in the molecular epidemiology of colorectal cancer study

33. P046 Occupational exposures and gastric cancer risk in the MCC-spain case-control study

34. P056 Occupational exposure to metals and risk of breast, chronic lymphocytic leukaemia, colorectal, prostate, and stomach cancer in the MCC-spain case control study

35. O06-4 Night shift work and stomach cancer risk in the MCC-spain study

36. O14-2 Breast cancer and occupational exposures in the mcc-spain study

37. O10-1 Occupational exposure to extremely low frequency magnetic fields and risk of breast cancer in the mcc-spain study

39. Abstract 4612: Genetic variants in epigenetic pathways and risk of multiple cancer types in the GAME-ON consortium

42. Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study.

45. High-accuracy network monitoring using ETOMIC testbed

Catalog

Books, media, physical & digital resources